Core Viewpoint - A securities fraud lawsuit has been filed against Maravai LifeSciences Holdings, Inc. and certain executives due to issues related to revenue recognition and internal controls [1][3]. Group 1: Company Announcement - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release and the filing of its annual report on Form 10-K due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [2]. - The company identified a material weakness in its internal controls over revenue recognition and required additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2]. Group 2: Stock Market Reaction - Following the announcement, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, with unusually heavy trading volume [2]. Group 3: Lawsuit Allegations - The lawsuit alleges that Maravai failed to disclose inadequate internal controls over financial reporting related to revenue recognition, leading to inaccurate revenue recognition during fiscal 2024 and an overstated goodwill [3]. - It is claimed that the positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [3]. Group 4: Investor Eligibility - Investors who purchased Maravai common stock between August 7, 2024, and February 24, 2025, and experienced a decline in share value may be eligible to participate in the lawsuit [4]. Group 5: Next Steps for Investors - The deadline for seeking appointment as lead plaintiff is May 5, 2025, and a class has not yet been certified [5]. - Investors are encouraged to contact Block & Leviton for more information regarding their potential claims [5]. Group 6: Whistleblower Information - Individuals with non-public information about Maravai are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, which may offer rewards of up to 30% of any successful recovery [6]. Group 7: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].
MRVI LAWSUIT: Maravai LifeSciences Holdings Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses